S&P 500
5,940.46
-0.4%
-23.14
DJI
42,677.24
-0.3%
-114.83
NASDAQ
$19,142.71
-0.4%
-$72.75
Bitcoin
106,693.00
+1.6%
+1,658.98
AAPL
$206.73
-1.0%
-$2.05
AMZN
$204.08
-1.0%
-$2.08
GOOG
$165.14
-1.6%
-$2.73
META
$636.43
-0.6%
-$4.00
MSFT
$457.90
-0.2%
-$0.97
NVDA
$134.22
-1.0%
-$1.34
TSLA
$343.52
+0.4%
+$1.43
Innate Pharma (NASDAQ: IPHA)
$2.10
(1.0%)
$0.02
Price as of May 20, 2025, 2:49 p.m. ET
Innate Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Innate Pharma Company Info
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.